Premium
Value of TAT and PIC with D‐dimer for cancer patients with metastasis
Author(s) -
Cui Chanjuan,
Gao Jia,
Li Jia,
Yu Mengyao,
Zhang Hao,
Cui Wei
Publication year - 2020
Publication title -
international journal of laboratory hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.705
H-Index - 55
eISSN - 1751-553X
pISSN - 1751-5521
DOI - 10.1111/ijlh.13194
Subject(s) - d dimer , metastasis , cancer , medicine , dimer , immunoassay , gastroenterology , oncology , chemistry , immunology , antibody , organic chemistry
The hypercoagulability of blood is related to the development and metastasis of cancer. High levels of D‐dimer have been reported to be associated with the metastasis and poor prognoses of cancer. Here, we investigated the performance of biomarkers — TAT, PIC, TM, and tPAI·C by new method — for monitoring cancer patients with metastasis. Methods A total of 197 cancer patients were enrolled. TM, TAT, PIC, and tPAI·C were detected by the chemiluminescence immunoassay. Results Results showed that the levels of TAT and PIC were higher in the metastasis group than those in the nonmetastasis group ( P < .01). In the nonmetastasis group, there were 16 patients with elevated levels of D‐dimer. But, TAT and PIC in these 16 patients were all at normal level (<0.55 mg/L FEU). After dilution, D‐dimer was also decreased to normal levels in these 16 patients. The ROC was used to show the performance of D‐dimer, TAT, and PIC on indicating cancer with metastasis. The AUC of PIC was higher than that of D‐dimer (0.825 vs. 0.770). The specificity and PPV of TAT and PIC were higher than those of D‐dimer. Serial test of TAT, PIC, and D‐dimer improved the specificity and positive predictive value to 90.91% [80.61%, 96.25%] and 89.29% [77.45%, 95.57%], respectively. Conclusion Combining TAT and PIC with D‐dimer could be useful surveillance biomarkers for cancer with metastasis.